Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Frontotemporal Disorders Treatment Market Overview

[213 Pages Report] The global Frontotemporal Disorders Treatment Market value at around US$ 343.8 million in 2022, registering Y-o-Y growth of 4.4%. The market is projected to increase at a CAGR of 4.6% and reach a valuation of US$ 451.4 million by 2028.

Attribute Details
Frontotemporal Disorders Treatment Market Size (2022) US$ 343.8 million
Sales Forecast (2028) US$ 451.4 million
Global Market Growth Rate (2022 to 2028) 4.6% CAGR
Share of Top 5 Frontotemporal Disorders Treatment System Providers 50%

Currently, frontotemporal disorders treatment holds a share of 4.4% of the global neurological disorder treatment market.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

How The Market Progressed Till June 2022?

Particulars Details
H1, 2021 4.69%
H1, 2022 Projected 4.64%
H1, 2022 Outlook 4.44%
BPS Change - H1, 2022 (O) - H1, 2022 (P) (-) 20 ↓
BPS Change - H1, 2022 (O) - H1, 2021 (-) 25 ↓

As per the FMI analysis, H1-2022 outlook period in comparison to H1-2022 projected period showed a negative growth in terms of Basis Point Share by 20 BPS. However, In H1-2022, the market growth rate of frontotemporal disorders treatment is expected to fall by 25 basis point share (BPS).

The decline in the BPS values observed was attributed the fact that there exist no current disease-modifying drugs approved by the regulatory bodies for the treatment of frontotemporal disorders. With growing changes in lifestyle, and the growing global burden of disease in ageing population, the market faced a heavy demand over the last few decades. With a large gap in the demand and supply, the market likely observed this decline in the BPS values.

Conversely, with advancements in behavioural therapy approaches, the management of symptomatic concerns regarding frontotemporal disorders will provide insights into the growth of the overall market during the forecast years.

The market is highly influenced by patient pool, treatment adoption rate, target population group demography, and disease prevalence, under the impact of macro and industry factors.

Frontotemporal Disorders Treatment Demand Analysis (2013-2021) Compared to Market Forecasts (2022-2028)

“Growing Prevalence of Dementia Expected to Propel Demand for Frontotemporal Disorders Treatment Drugs”

During the historical period of 2013 to 2021, the frontotemporal disorders treatment market expanded at a CAGR of 4.4%.

Frontotemporal disorders are a bunch of rare disorders that include shrinkage of a particular portion of the brain that controls personality, language, and behavior. The condition arises due to the degeneration of frontotemporal cells, which is called frontotemporal lobar degeneration (FTLD).

The typical age range for the onset of frontotemporal dementia is 40 to 60 years; however, it can start after 60 years of age, and the maximum life expectancy after diagnosis is 8–10 years.

With severe dearth of frontotemporal disorders treatment drugs for the reliable treatment of frontotemporal disorders, treatment continues to underscore the growing significance of disease management. As frontotemporal disorders treatment exclusively includes symptomatic efforts to date, the condition continues to attract research interests worldwide.

Frontotemporal Disorders Treatment Market

Available frontotemporal disorders treatment drugs and other means of frontotemporal disorders treatment do not stop or even decelerate frontotemporal disorders progression, which further remains a key driving force for growing demand for frontotemporal disorders treatment. Expanding incentives for orphan drug development is identified as a prominent factor pushing revenue growth of the frontotemporal disorders treatment industry.

Considering the aforementioned factors, the global frontotemporal disorders treatment market is anticipated to rise at 4.6% CAGR across the 2022 to 2028 time frame.

What are the Prominent Driving Factors for Frontotemporal Disorders Treatment?

“Increasing FTD Drug Development Grants & Funding by Non-Profit Organizations Driving Market Growth”

Non-profit organizations and disease advocacy & private organizations currently are focusing on supporting FTD drug development as the patient base of FTD is expanding. Research funding initiatives by non-profit organizations such as the Association for Frontotemporal Degeneration (AFTD), Alzheimer Discovery Foundation (ADDF), Bluefield Project Organization, Tau Consortium Organization, and CurePSP, Inc. have helped promote research initiatives in frontotemporal disorders treatment drugs.

These organizations support clinical trials as well as preclinical studies for testing new therapeutics that are interventional to slow or stop FTD and other rare neurological disease progressions.

Rising life expectancy rate is another major factor expected to boost the growth of the frontotemporal disorders treatment market due to the high prevalence of neurological disease among the older population. Population aged 65 years and above is mostly prone to neurodegenerative diseases such as frontotemporal disorder, Alzheimer’s, and dementia.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Which Factors are Restraining Demand for Frontotemporal Disorders Treatment?

“Misdiagnosis and Lack of Awareness Limiting Adoption of Neurological Conditions Treatment

Frontotemporal disorders are often misdiagnosed as depression, Parkinson’s, Alzheimer’s, or other psychiatric conditions, thereby limiting the scope of adoption of neurological conditions treatment.

Though clinical trials have resulted in many interventions other than medication, consistently high rate of clinical trial failures is a significant factor that is influencing the growth prospects of neurological conditions treatment.

Which is the Dominant Regional Market for Frontotemporal Disorders Treatment?

“Ongoing Clinical Trials for Frontotemporal Lobar Degeneration (FTLD) to Boost Market Expansion in Western Europe”

Western Europe is expected to contribute 30.5% share in the global frontotemporal disorders treatment market in 2022.

While rapidly growing FTD prevalence and expanding ongoing clinical trials platforms are providing a collective push to the frontotemporal disorders treatment market in Western Europe, research estimates rapid emergence owing to increasing sophistication of the healthcare sector and gradually surging awareness about frontotemporal lobar degeneration (FTLD).

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Country-wise Analysis

What Potential Does the U.S. Frontotemporal Disorders Treatment Market Hold?

“Orphan Drug Development Incentives by FDA to Push the Market Forward”

Frontotemporal dementia falls under rare diseases or orphan indications. FTD affects around 30,000 to 40,000 patients in the U.S. Treatment of FTD falls under auspices of the Orphan Drug Act of 1983 as orphan drug indications are those that affect less than 200,000 people in the U.S.

Orphan drug designation to FTD allows the continuation of clinical trial and orphan drug development with commercial incentives, prioritized consultation by FDA on clinical studies, and reduction in regulatory fees.

Presence of advanced healthcare facilities, stronger purchasing power for expensive pharmaceuticals, reimbursement regulations, and an expanding patient pool is expected to fuel market growth in the U.S.

How is the Market for Frontotemporal Disorders Treatment Faring in China?

“Higher Prevalence of Frontotemporal Disorders in Older Age Group to Fuel Market Expansion”

China, with an attractive revenue contribution at present, is projected to remain a highly lucrative regional market for potential investors in the frontotemporal disorders treatment systems market.

The market in China is predicted to develop at the quickest rate due to increased disposable income. Moreover, the market growth is related to increasing prevalence of frontotemporal disorders due to the growing elderly population base, as well as the poor immune system.

Category-wise Insights

Which Disease Indication Will Hold Maximum Sway?

“Initiatives by Mental Treatment Centers for Frontotemporal Dementia Patients to Boost Market Growth”

Based on disease indication, frontotemporal dementia (FTD), holding a massive market value share, remains the most common indication among all that continues to capture clinical research interests.

Rapid development of new frontotemporal dementia therapies will push collaborative activities among clinical research entities, educational institutions, academic laboratories, pharma and biotech centers, and the FDA.

Furthermore, frontotemporal dementia therapeutics are anticipated to witness major contributions from pharmaceutical companies – eventually boosting the funding and clinical trial scenario.

Which Distribution Channel is Driving Demand for Frontotemporal Disorders Treatment Products?

“Hospital Pharmacies Most Preferred Due to Easy Availability of Frontotemporal Disorders Treatment Drugs”

Hospital pharmacies are expected to hold the highest market share over the forecast period. Majority of frontotemporal problems are treated in hospitals, and with the availability of trained medical personnel, it is simpler to control an individual's health more correctly.

However, there are no specific treatments available to entirely stop the course of frontotemporal disorders. As a result, doctors may prescribe antidepressant medicines to help with anxiety and other symptoms.

Impact of COVID-19 on Market

The frontotemporal disorders treatment market, like many others, was heavily damaged by the COVID-19 pandemic. An increase in infection fear among persons of all ages has resulted from an increasing number of COVID-positive cases that have resulted in mortality and morbidity all across the world.

In addition, limits on travel and movement, social distance conventions, and hospital beds reserved for COVID patients reduced clinical and hospital visits.

However, the emergence of virtual healthcare consultations and remote patient monitoring, as well as an increase in COVID-19 vaccines and lifting of lockdown limitations, will enable the market for frontotemporal disorders treatment devices to quickly recover and grow significantly over the coming years.

Competitive Landscape

In a highly fragmented landscape of the global frontotemporal disorders treatment market, almost 70% of companies offer generics as their key drug offerings. Operated by a large number of prominent international, multinational, and regional players, the market for frontotemporal disorders treatment is recently witnessing a heap of strategic deals, including acquisitions, collaborations, and alliances.

For instance,

  • AstraZeneca Plc recently inked an agreement with Luye Pharma Group, Ltd. over the licensing and sales of Seroquel and Seroquel XR across China and the U.K, in addition to a few other international markets. The drug is occasionally used to address a set of behavioral problems associated with FTD.

Frontotemporal Disorders Treatment Industry Report Scope

Attribute Details
Forecast Period 2022 to 2028
Historical Data Available for 2013 to 2021
Market Analysis Value in US$ million
Key Regions Covered
  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia & Pacific
  • Middle East & Africa (MEA)
Key Countries Covered
  • USA
  • Canada
  • Mexico
  • Brazil
  • Mexico
  • Argentina
  • Germany
  • Italy
  • France
  • UK
  • Nordic
  • Spain
  • Japan
  • China
  • India
  • Malaysia
  • Thailand
  • Australia
  • GCC Countries
  • South Africa
  • Turkey
Key Market Segments Covered
  • Drug Class
  • Treatment
  • Disease Indication
  • Distribution Channel
  • Region
Key Companies Profiled
  • Pfizer Inc.
  • Johnson & Johnson
  • Sanofi S.A.
  • Eli Lilly and Company
  • GlaxoSmithKline Plc.
  • Novartis AG
  • Mylan N.V.
  • Merck & Company, Inc.
  • AstraZeneca plc.
  • Allergen plc
Pricing Available upon Request

Key Segments of Frontotemporal Disorders Treatment Industry Research

By Drug Class:

  • Cognitive Enhancers
  • Antipsychotics
  • Antidepressants
  • CNS Stimulants
  • Others

By Treatment:

  • Behavioral Symptoms Management
  • Psychological Symptoms Management

By Disease Indication:

  • Frontotemporal Dementia
  • Primary Progressive Aphasia
  • Movement Disorders

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

By Region:

  • North America Frontotemporal Disorders Treatment Market
  • Latin America Frontotemporal Disorders Treatment Market
  • Europe Frontotemporal Disorders Treatment Market
  • East Asia Frontotemporal Disorders Treatment Market
  • South Asia & Pacific Frontotemporal Disorders Treatment Market
  • Middle East & Africa (MEA) Frontotemporal Disorders Treatment Market

Frequently Asked Questions

How much is the frontotemporal disorders treatment market expected to be worth in 2022?

As of 2022, the global frontotemporal disorders treatment market is expected to reach US$ 343.8 Mn.

Which are the top 5 countries driving demand for frontotemporal disorders treatment?

France, China, Germany, India, and the U.S. are the top 5 countries driving most demand for frontotemporal disorders treatment.

Which are the leading companies manufacturing frontotemporal disorders treatment products?

Pfizer Inc., Johnson & Johnson, Sanofi S.A., Eli Lilly and Company, and GlaxoSmithKline Plc. are leading companies in this market.

What is the future growth rate of the frontotemporal disorders treatment market for the forecast period?

The frontotemporal disorders treatment market is expected to rise at a CAGR of around 4.6% during the period of 2022-2028.

Which region has the largest market for frontotemporal disorders treatment?

Western Europe accounts for 30.5% share of the global frontotemporal disorders treatment market.

Table of Content

1. Executive Summary

    1.1. Market Overview

    1.2. Market Analysis

    1.3. FMI Analysis and Recommendations

    1.4. Wheel of Fortune

2. Market Introduction

    2.1. Market Taxonomy

    2.2. Market Definition

3. Frontotemporal Disorders Treatment Market Opportunity Analysis

    3.1. Macro-Economic Factors

    3.2. Opportunity Analysis & Pipeline Assessment

4. Market Background

    4.1. Market Dynamics

        4.1.1. Drivers

        4.1.2. Restraints

        4.1.3. Trends

5. Key Inclusions

    5.1. Disease Epidemiology

6. North America Frontotemporal Disorders Treatment Market Analysis 2013-2021 and Forecast 2022–2028

    6.1. Introduction

    6.2. Historical Market Value (US$ Mn) Analysis By Country, 2013-2021

        6.2.1. U.S.

        6.2.2. Canada

    6.3. Market Value (US$ Mn) Forecast By Country, 2022–2028

    6.4. Historical Market Value (US$ Mn) Analysis By Drug Class, 2013-2021

        6.4.1. Cognitive Enhancers

        6.4.2. Antipsychotics

        6.4.3. Antidepressants

        6.4.4. CNS Stimulants

        6.4.5. Others

    6.5. Market Value (US$ Mn) Forecast By Drug Class, 2022–2028

    6.6. Historical Market Value (US$ Mn) Trend Analysis By Treatment Type, 2013-2021

        6.6.1. Behavioral Symptom Management

        6.6.2. Psychological Symptoms Management

    6.7. Market Value (US$ Mn) Forecast By Treatment Type, 2022–2028

    6.8. Historical Market Value (US$ Mn) Trend Analysis By Disease Indication, 2013-2021

        6.8.1. Frontotemporal Dementia

        6.8.2. Primary Progressive Aphasia

        6.8.3. Movement Disorders

    6.9. Market Value (US$ Mn) Forecast By Disease Indication, 2022–2028

    6.10. Historical Market Value (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021

        6.10.1. Hospital Pharmacies

        6.10.2. Retail Pharmacy

        6.10.3. Drug Stores

        6.10.4. Online Pharmacy

    6.11. Market Value (US$ Mn) Forecast By Distribution Channel, 2022–2028

    6.12. Market Attractiveness Analysis

        6.12.1. By Country

        6.12.2. By Drug Class

        6.12.3. By Treatment Type

        6.12.4. By Disease Indication

        6.12.5. By Distribution Channel

7. Latin America Frontotemporal Disorders Treatment Market Analysis 2013-2021 and Forecast 2022–2028

    7.1. Introduction

    7.2. Historical Market Value (US$ Mn) Analysis By Country, 2013-2021

        7.2.1. Brazil

        7.2.2. Mexico

        7.2.3. Rest of Latin America

    7.3. Market Value (US$ Mn) Forecast By Country, 2022–2028

    7.4. Historical Market Value (US$ Mn) Analysis By Drug Class, 2013-2021

        7.4.1. Cognitive Enhancers

        7.4.2. Antipsychotics

        7.4.3. Antidepressants

        7.4.4. CNS Stimulants

        7.4.5. Others

    7.5. Market Value (US$ Mn) Forecast By Drug Class, 2022–2028

    7.6. Historical Market Value (US$ Mn) Trend Analysis By Treatment Type, 2013-2021

        7.6.1. Behavioral Symptom Management

        7.6.2. Psychological Symptoms Management

    7.7. Market Value (US$ Mn) Forecast By Treatment Type, 2022–2028

    7.8. Historical Market Value (US$ Mn) Trend Analysis By Disease Indication, 2013-2021

        7.8.1. Frontotemporal Dementia

        7.8.2. Primary Progressive Aphasia

        7.8.3. Movement Disorders

    7.9. Market Value (US$ Mn) Forecast By Disease Indication, 2022–2028

    7.10. Historical Market Value (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021

        7.10.1. Hospital Pharmacies

        7.10.2. Retail Pharmacy

        7.10.3. Drug Stores

        7.10.4. Online Pharmacy

    7.11. Market Value (US$ Mn) Forecast By Distribution Channel, 2022–2028

    7.12. Market Attractiveness Analysis

        7.12.1. By Country

        7.12.2. By Drug Class

        7.12.3. By Treatment Type

        7.12.4. By Disease Indication

        7.12.5. By Distribution Channel

8. Western Europe Frontotemporal Disorders Treatment Market Analysis 2013-2021 and Forecast 2022–2028

    8.1. Introduction

    8.2. Historical Market Value (US$ Mn) Analysis By Country, 2013-2021

        8.2.1. Germany

        8.2.2. U.K

        8.2.3. France

        8.2.4. Italy

        8.2.5. Spain

        8.2.6. Rest of Western Europe

    8.3. Market Value (US$ Mn) Forecast By Country, 2022–2028

    8.4. Historical Market Value (US$ Mn) Analysis By Drug Class, 2013-2021

        8.4.1. Cognitive Enhancers

        8.4.2. Antipsychotics

        8.4.3. Antidepressants

        8.4.4. CNS Stimulants

        8.4.5. Others

    8.5. Market Value (US$ Mn) Forecast By Drug Class, 2022–2028

    8.6. Historical Market Value (US$ Mn) Trend Analysis By Treatment Type, 2013-2021

        8.6.1. Behavioral Symptom Management

        8.6.2. Psychological Symptoms Management

    8.7. Market Value (US$ Mn) Forecast By Treatment Type, 2022–2028

    8.8. Historical Market Value (US$ Mn) Trend Analysis By Disease Indication, 2013-2021

        8.8.1. Frontotemporal Dementia

        8.8.2. Primary Progressive Aphasia

        8.8.3. Movement Disorders

    8.9. Market Value (US$ Mn) Forecast By Disease Indication, 2022–2028

    8.10. Historical Market Value (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021

        8.10.1. Hospital Pharmacies

        8.10.2. Retail Pharmacy

        8.10.3. Drug Stores

        8.10.4. Online Pharmacy

    8.11. Market Value (US$ Mn) Forecast By Distribution Channel, 2022–2028

    8.12. Market Attractiveness Analysis

        8.12.1. By Country

        8.12.2. By Drug Class

        8.12.3. By Treatment Type

        8.12.4. By Disease Indication

        8.12.5. By Distribution Channel

9. Eastern Europe Frontotemporal Disorders Treatment Market Analysis 2013-2021 and Forecast 2022–2028

    9.1. Introduction

    9.2. Historical Market Value (US$ Mn) Analysis By Country, 2013-2021

        9.2.1. Russia

        9.2.2. Poland

        9.2.3. Rest of Eastern Europe

    9.3. Market Value (US$ Mn) Forecast By Country, 2022–2028

    9.4. Historical Market Value (US$ Mn) Analysis By Drug Class, 2013-2021

        9.4.1. Cognitive Enhancers

        9.4.2. Antipsychotics

        9.4.3. Antidepressants

        9.4.4. CNS Stimulants

        9.4.5. Others

    9.5. Market Value (US$ Mn) Forecast By Drug Class, 2022–2028

    9.6. Historical Market Value (US$ Mn) Trend Analysis By Treatment Type, 2013-2021

        9.6.1. Behavioral Symptom Management

        9.6.2. Psychological Symptoms Management

    9.7. Market Value (US$ Mn) Forecast By Treatment Type, 2022–2028

    9.8. Historical Market Value (US$ Mn) Trend Analysis By Disease Indication, 2013-2021

        9.8.1. Frontotemporal Dementia

        9.8.2. Primary Progressive Aphasia

        9.8.3. Movement Disorders

    9.9. Market Value (US$ Mn) Forecast By Disease Indication, 2022–2028

    9.10. Historical Market Value (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021

        9.10.1. Hospital Pharmacies

        9.10.2. Retail Pharmacy

        9.10.3. Drug Stores

        9.10.4. Online Pharmacy

    9.11. Market Value (US$ Mn) Forecast By Distribution Channel, 2022–2028

    9.12. Market Attractiveness Analysis

        9.12.1. By Country

        9.12.2. By Drug Class

        9.12.3. By Treatment Type

        9.12.4. By Disease Indication

        9.12.5. By Distribution Channel

10. Asia Pacific Excluding Japan (APEJ) Frontotemporal Disorders Treatment Market Analysis 2013-2021 and Forecast 2022–2028

    10.1. Introduction

    10.2. Historical Market Value (US$ Mn) Analysis By Country, 2013-2021

        10.2.1. India

        10.2.2. China

        10.2.3. Australia

        10.2.4. ASEAN

        10.2.5. Rest of APEJ

    10.3. Market Value (US$ Mn) Forecast By Country, 2022–2028

    10.4. Historical Market Value (US$ Mn) Analysis By Drug Class, 2013-2021

        10.4.1. Cognitive Enhancers

        10.4.2. Antipsychotics

        10.4.3. Antidepressants

        10.4.4. CNS Stimulants

        10.4.5. Others

    10.5. Market Value (US$ Mn) Forecast By Drug Class, 2022–2028

    10.6. Historical Market Value (US$ Mn) Trend Analysis By Treatment Type, 2013-2021

        10.6.1. Behavioral Symptom Management

        10.6.2. Psychological Symptoms Management

    10.7. Market Value (US$ Mn) Forecast By Treatment Type, 2022–2028

    10.8. Historical Market Value (US$ Mn) Trend Analysis By Disease Indication, 2013-2021

        10.8.1. Frontotemporal Dementia

        10.8.2. Primary Progressive Aphasia

        10.8.3. Movement Disorders

    10.9. Market Value (US$ Mn) Forecast By Disease Indication, 2022–2028

    10.10. Historical Market Value (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021

        10.10.1. Hospital Pharmacies

        10.10.2. Retail Pharmacy

        10.10.3. Drug Stores

        10.10.4. Online Pharmacy

    10.11. Market Value (US$ Mn) Forecast By Distribution Channel, 2022–2028

    10.12. Market Attractiveness Analysis

        10.12.1. By Country

        10.12.2. By Drug Class

        10.12.3. By Treatment Type

        10.12.4. By Disease Indication

        10.12.5. By Distribution Channel

11. Japan Frontotemporal Disorders Treatment Market Analysis 2013-2021 and Forecast 2022–2028

    11.1. Introduction

    11.2. Historical Market Value (US$ Mn) Analysis By Drug Class, 2013-2021

        11.2.1. Cognitive Enhancers

        11.2.2. Antipsychotics

        11.2.3. Antidepressants

        11.2.4. CNS Stimulants

        11.2.5. Others

    11.3. Market Value (US$ Mn) Forecast By Drug Class, 2022–2028

    11.4. Historical Market Value (US$ Mn) Trend Analysis By Treatment Type, 2013-2021

        11.4.1. Behavioral Symptom Management

        11.4.2. Psychological Symptoms Management

    11.5. Market Value (US$ Mn) Forecast By Treatment Type, 2022–2028

    11.6. Historical Market Value (US$ Mn) Trend Analysis By Disease Indication, 2013-2021

        11.6.1. Frontotemporal Dementia

        11.6.2. Primary Progressive Aphasia

        11.6.3. Movement Disorders

    11.7. Market Value (US$ Mn) Forecast By Disease Indication, 2022–2028

    11.8. Historical Market Value (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021

        11.8.1. Hospital Pharmacies

        11.8.2. Retail Pharmacy

        11.8.3. Drug Stores

        11.8.4. Online Pharmacy

    11.9. Market Value (US$ Mn) Forecast By Distribution Channel, 2022–2028

    11.10. Market Attractiveness Analysis

        11.10.1. By Country

        11.10.2. By Drug Class

        11.10.3. By Treatment Type

        11.10.4. By Disease Indication

        11.10.5. By Distribution Channel

12. Middle East and Africa Frontotemporal Disorders Treatment Market Analysis 2013-2021 and Forecast 2022–2028

    12.1. Introduction

    12.2. Historical Market Value (US$ Mn) Analysis By Country, 2013-2021

        12.2.1. GCC Countries

        12.2.2. South Africa

        12.2.3. Rest of MEA

    12.3. Market Value (US$ Mn) Forecast By Country, 2022–2028

    12.4. Historical Market Value (US$ Mn) Analysis By Drug Class, 2013-2021

        12.4.1. Cognitive Enhancers

        12.4.2. Antipsychotics

        12.4.3. Antidepressants

        12.4.4. CNS Stimulants

        12.4.5. Others

    12.5. Market Value (US$ Mn) Forecast By Drug Class, 2022–2028

    12.6. Historical Market Value (US$ Mn) Trend Analysis By Treatment Type, 2013-2021

        12.6.1. Behavioral Symptom Management

        12.6.2. Psychological Symptoms Management

    12.7. Market Value (US$ Mn) Forecast By Treatment Type, 2022–2028

    12.8. Historical Market Value (US$ Mn) Trend Analysis By Disease Indication, 2013-2021

        12.8.1. Frontotemporal Dementia

        12.8.2. Primary Progressive Aphasia

        12.8.3. Movement Disorders

    12.9. Market Value (US$ Mn) Forecast By Disease Indication, 2022–2028

    12.10. Historical Market Value (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021

        12.10.1. Hospital Pharmacies

        12.10.2. Retail Pharmacy

        12.10.3. Drug Stores

        12.10.4. Online Pharmacy

    12.11. Market Value (US$ Mn) Forecast By Distribution Channel, 2022–2028

    12.12. Market Attractiveness Analysis

        12.12.1. By Country

        12.12.2. By Drug Class

        12.12.3. By Treatment Type

        12.12.4. By Disease Indication

        12.12.5. By Distribution Channel

13. Forecast Factors: Relevance and Impact

14. Driver Restraint Impact Analysis

15. Market Structure Analysis

16. Competition Analysis

    16.1. Competition Dashboard

    16.2. Competition Benchmarking

    16.3. Profitability and Gross Margin Analysis By Competition

    16.4. Competitors Deep Dive (Company Overview, Footprint, Strategies, Financials, Key Development)

        16.4.1. Pfizer Inc.

        16.4.2. Johnson & Johnson

        16.4.3. Sanofi S.A.

        16.4.4. Eli Lilly and Company

        16.4.5. GlaxoSmithKline Plc.

        16.4.6. GlaxoSmithKline Plc.

        16.4.7. Mylan N.V.

        16.4.8. Merck & Company, Inc.

        16.4.9. AstraZeneca plc.

        16.4.10. Allergan Plc.

17. Global Frontotemporal Disorders Treatment Market Analysis 2013-2021 and Forecast 2022–2028 By Region

    17.1. Introduction / Key Findings

    17.2. Historical Market Value (US$ Mn) Analysis By Region

        17.2.1. North America

        17.2.2. Western Europe

        17.2.3. Eastern Europe

        17.2.4. Latin America

        17.2.5. Asia Pacific Excluding Japan

        17.2.6. Japan

        17.2.7. Middle East and Africa

    17.3. Market Value (US$ Mn) Forecast By Region

    17.4. Market Attractiveness Analysis By Region

18. Global Frontotemporal Disorders Treatment Market Analysis 2013-2021 and Forecast 2022–2028, By Drug Class

    18.1. Introduction/Key Finding

    18.2. Historical Market Value (US$ Mn) Analysis By Drug Class, 2013-2021

        18.2.1. Cognitive Enhancers

        18.2.2. Antipsychotics

        18.2.3. Antidepressants

        18.2.4. CNS Stimulants

        18.2.5. Others

    18.3. Market Value (US$ Mn) Forecast By Drug Class, 2022–2028

    18.4. Market Attractiveness Analysis By Drug Class

19. Global Frontotemporal Disorders Treatment Market Analysis 2013-2021 and Forecast 2022–2028, By Treatment Type

    19.1. Introduction/Key Finding

    19.2. Historical Market Value (US$ Mn) Analysis By Treatment Type, 2013-2021

        19.2.1. Frontotemporal Dementia

        19.2.2. Primary Progressive Aphasia

        19.2.3. Movement Disorders

    19.3. Market Value (US$ Mn) Forecast By Treatment Type, 2022–2028

    19.4. Market Attractiveness Analysis By Treatment Type

20. Global Frontotemporal Disorders Treatment Market Analysis 2013-2021 and Forecast 2022–2028, By Disease Indication

    20.1. Introduction/Key Finding

    20.2. Historical Market Value (US$ Mn) Analysis By Disease Indication, 2013-2021

        20.2.1. Frontotemporal Dementia

        20.2.2. Primary Progressive Aphasia

        20.2.3. Movement Disorders

    20.3. Market Value (US$ Mn) Forecast By Disease Indication, 2022–2028

    20.4. Market Attractiveness Analysis By Disease Indication

21. Global Frontotemporal Disorders Treatment Market Analysis 2013-2021 and Forecast 2022–2028, By Distribution Channel

    21.1. Introduction/Key Finding

    21.2. Historical Market Value (US$ Mn) Analysis By Distribution Channel, 2013-2021

        21.2.1. Hospital Pharmacies

        21.2.2. Retail Pharmacy

        21.2.3. Drug Stores

        21.2.4. Online Pharmacy

    21.3. Market Value (US$ Mn) Forecast By Distribution Channel, 2022–2028

    21.4. Market Attractiveness Analysis By Distribution Channel

22. Global Frontotemporal Disorders Treatment Market Analysis 2013-2021 and Forecast 2022–2028

    22.1. Market Value Share Analysis By All Segment

    22.2. Y-o-Y Growth Analysis By All Segment

    22.3. Absolute $ Opportunity

23. Assumptions and Acronyms Used

24. Research Methodology

Recommendations

Healthcare

Gamma Knife Market

Published : October 2023

Healthcare

Brain Monitoring Systems Market

Published : January 2023

Explore Healthcare Insights

View Reports

Frontotemporal Disorders Treatment Market